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New Drugs against Tuberculosis: Problems, Progress, and Evaluation
of Agents in Clinical Development
Jossy van den Boogaard,1* Gibson S. Kibiki,2 Elton R. Kisanga,2
Martin J. Boeree,1 and Rob E. Aarnoutse1
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands,1 and
Kilimanjaro Christian Medical Centre, Moshi, Tanzania2
One-third of the world population is infected with Mycobac-
terium tuberculosis (MTB) and hence at risk of developing
active tuberculosis (TB). Each year, 8.8 million patients are
newly diagnosed with active TB and 1.6 million patients die of
TB. The rapid spread of the human immunodeficiency virus
(HIV) has fueled the TB epidemic, especially in sub-Saharan
Africa, where 28% of TB patients are HIV positive (176). The
current first-line treatment for TB is a multidrug regimen con-
sisting of rifampin, isoniazid, pyrazinamide, and ethambutol
(RHZE). It must be taken for at least 6 months to achieve high
cure rates (more than 95% in experimental settings).
PROBLEMS WITH CURRENT
TUBERCULOSIS TREATMENT
There are several major problems associated with the cur-
rently available TB treatment. First, the duration and complex-
ity of treatment result in nonadherence to treatment. This
leads to suboptimal response (failure and relapse), the emer-
gence of resistance, and continuous spread of the disease
(168). Second, adverse events in response to anti-TB drugs are
common and contribute to the problem of nonadherence (19,
168). Third, the increasing incidence of multidrug-resistant
(MDR; resistance to at least rifampin and isoniazid) and ex-
tensively drug-resistant (XDR; MDR resistance plus resistance
to a fluoroquinolone and an aminoglycoside) TB is a serious
concern. Resistant TB occurs in the presence of partially sup-
pressive drug concentrations that enable replication of bacte-
ria, the formation of mutants, and overgrowth of wild-type
strains by mutants (selective pressure) (175). The prevalence
of MDR TB in new TB cases ranged from 0% in some Western
European countries to more than 22% in Azerbaijan (2002 to
2007 survey); 14 of 72 participating countries reported an
MDR TB prevalence of more than 5% (177). Second-line
drugs for drug-resistant TB are not available everywhere and
are less effective, more toxic, and require longer use than
first-line drugs (61). Fourth, coinfection of TB and HIV is a
problem by itself. Combined treatment of TB and HIV in-
volves a high pill count with associated adherence problems,
overlapping toxicity profiles of the antiretroviral and anti-TB
drugs, drug interactions between rifampin and the antiretrovi-
ral protease inhibitors, and the risk of immune reconstitution
syndrome (104). Fifth, prophylactic therapy of latent TB (TB
infection without symptoms) with isoniazid is also associated
with problems of nonadherence (180). Attempts to shorten
treatment with alternative drugs resulted in severe adverse
events (64, 150, 155).
The World Health Organization (WHO) has developed the
directly observed therapy short course (DOTS) strategy to
optimize response and adherence to TB treatment. However,
DOTS is labor-intensive and expensive. It causes a high burden
on public health programs, especially in developing countries
with limited human resources (49). In addition, TB diagnosis in
the DOTS strategy is based on sputum microscopy, rather than
sputum culture (173). Only advanced pulmonary TB is de-
tected by sputum microscopy, and it requires qualified micros-
copists (115). Consequently, TB detection rates are suboptimal
and resistant M. tuberculosis strains are not detected (62, 115).
Clearly, there is an urgent need to improve treatment by
either enhancing the application of existing agents or intro-
ducing new drugs. Potential new agents should reduce treat-
ment duration, have an acceptable tolerability profile, be
active against MDR/XDR TB, be of use in HIV-infected pa-
tients with TB, and be active against latent TB (Table 1). The
aim of this article is to review the challenges of developing new
anti-TB drugs, to present an up-to-date and critical evaluation
of new agents in the phase of clinical testing, and to suggest
ways forward to improve TB treatment.
CHALLENGES OF DEVELOPING NEW ANTI-TB DRUGS
The rapid development of new anti-TB drugs has been ham-
pered by several obstacles. First of all, the TB drug market is
associated with insufficient profit opportunity or investment
return to instigate pharmaceutical industries to develop new
drugs. The cost of developing a new drug is estimated at $115
to $240 million (39). To be profitable, market prices of new
drugs should be relatively high, whereas the cost of the stan-
dard regimen is only about $11 per patient (115). In response
to the reluctance of pharmaceutical industries, governments
and nongovernmental organizations have started to invest in
TB drug research and development. In the 1990s, the United
States Centers for Disease Control and Prevention (CDC)
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established the Tuberculosis Trials Consortium (TBTC). In
2000, private and public sector partnerships formed the Global
Alliance for TB Drug Development (GATB), a nonprofit ven-
ture that supports the discovery and development of cost-
effective new drugs (49). Various other research consortia are
testing new drugs in preclinical and clinical trials. Large fund-
ing agencies, such as the European & Developing Countries
Clinical Trials Partnership (EDCTP) and the Bill & Melinda
Gates foundation are supporting these initiatives.
A second challenge in TB drug development is the diffi-
culty to identify new compounds with activity against M.
tuberculosis. Regimens against TB should kill both the rap-
idly growing mycobacteria (bactericidal activity) and the
persisting mycobacteria in lesions (sterilizing activity) (97).
The molecular mechanisms responsible for mycobacterial
dormancy (mycobacteria in a state of low metabolic activity
and not forming colonies), persistence (drug-susceptible
mycobacteria that manage to survive despite continuous ex-
posure to TB drugs), and drug resistance are not yet fully
understood (180). The deciphering of the mycobacterial ge-
nome in 1998 has been of help in elucidating regulatory
mechanisms of metabolic pathways and thereby revealing
new drug targets (6, 24).
A next challenge rises with the evaluation of new com-
pounds, as there are currently no animal models available that
predict with accuracy the required treatment duration with
newly identified compounds (98). The guinea pig model is
being explored as an alternative for the mouse model since it
resembles TB pathology in humans more closely (73).
The phase of clinical testing of new anti-TB drugs is time-
consuming, as the current “gold standard” to assess efficacy of
anti-TB regimens in phase III clinical trials is the relapse rate
2 years after completing treatment. In phase II clinical trials,
the sputum culture conversion rate after 2 months of treatment
is used as a surrogate marker for relapse rate, but the value of
this surrogate marker is controversial (95, 120). Several other
surrogate markers are under evaluation (120). Large sample
sizes are needed in phase III clinical trials to compare the
effective standard regimen to a new regimen, even in trials that
use a noninferiority design. This contributes to the length of
the TB drug development process (45).
Another challenge is the scarcity of trial sites with sufficient
research capacity to conduct clinical trials with large sample
sizes. Trials should be performed in countries where the TB
burden is highest, but the human and infrastructural capacity
for performing large, high-quality phase III clinical trials is
usually limited in these settings (45). Despite the challenges of
TB drug development, studies are being conducted with higher
doses of the rifamycins and several new drug candidates have
reached the phase of clinical testing.
OLD DRUGS REVISED: HIGHER DOSES
OF RIFAMYCINS
Rifampin. Rifampin is considered to be the cornerstone in
the current treatment of TB (16). Its standard dose in TB
treatment is 10 mg/kg of body weight, corresponding to 600 mg
in most populations. Results from studies with mice and early
bactericidal activity (EBA) studies in which the fall in CFU
during the first 2 days of treatment is studied suggest that the
standard dose of rifampin in TB treatment is at the lower end
of the concentration-response curve (30, 65, 96).
(i) Mechanism of action. Rifampin inhibits the -subunit of
the RNA polymerase, a multisubunit enzyme that transcribes
bacterial RNA (16). Mycobacterial resistance to the rifamycins
results from mutations in the rpoB gene that codes for the
-subunit of the RNA polymerase (40). About 95% of muta-
tions occur in a region of less than 100 bp of the rpoB gene
(52). The increasing prevalence of resistance to rifampin and
isoniazid (MDR TB) is a serious concern (177).
(ii) Pharmacokinetics. The pharmacokinetics of rifampin in
adults treated with the licensed dose (10 mg/kg of body weight)
are shown in Table 2 and have been reviewed elsewhere (16).
In the 1960s and 1970s, the pharmacokinetics of higher single
doses (up to 30 mg/kg) and repeated doses (up to 16 mg/kg) of
rifampin in adults were assessed, showing nonlinear increases
in exposure (1, 74). More recently, the pharmacokinetics of
daily rifampin at 13 mg/kg have been compared with 10 mg/kg
in 50 Indonesian patients with pulmonary TB who were treated
with the standard regimen (2 months of RHZE followed by 4
months of rifampin and isoniazid [2RHZE/4RH]) (133). In-
creasing the dose by 30% increased the peak concentration of
rifampin in plasma (Cmax) by 49%; the area under the plasma
concentration-time curve (AUC) increased by 65%. AUC is an
important parameter for concentration-dependent killers such
as the rifamycins. It indicates total exposure to the drug over a
TABLE 1. Required properties of new anti-TB drugs
What a new drug should do Characteristic(s) required
Simplify treatment or reduce treatment duration Strong (early) bactericidal and sterilizing activity
Low pill count, fixed-dose combinations
Allow for intermittent therapy
Have an acceptable toxicity profile Low incidence of treatment-limiting adverse events
No overlapping toxicity profile with other TB drugs
Be active against MDR/XDR TB No cross-resistance with first-line drugs
Be useful in HIV-infected patients with TB Minimal interactions with antiretroviral drugs
No overlapping toxicity profile with antiretroviral drugs
Be active against latent TB Activity against dormant bacilli
Favorable toxicity profile
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certain time period. In a recent EBA study, a 71% increase in
AUC was seen with a 67% increase in rifampin dose from 12
to 20 mg/kg after 5 days of monotherapy (30). A higher dose of
rifampin is not likely to affect the pharmacokinetics of other
anti-TB drugs and antiretroviral drugs more strongly than the
standard dose, as rifampin’s inductive effect on the cytochrome
P450 (CYP450) enzyme system appears to be maximal at a
daily dose of 300 mg (105).
(iii) Pharmacodynamics and efficacy. The MIC of rifampin
is 0.15 mg/liter in broth culture (16, 53). Rifampin exhibits
concentration-dependent activity that correlates best with the
AUC/MIC ratio, as was shown in the mouse model (16, 108).
Results from an efficacy study in mice predicted a one-third
reduction in TB treatment duration when the rifampin dose
was increased by 50% (65). Only a few data are available on
the efficacy of regimens based on a higher dose of rifampin in
humans. A short regimen of a high dose of rifampin (1,200 mg
daily or every other day) with a high dose of isoniazid (900 mg)
and streptomycin (1,000 mg) daily yielded almost 100% spu-
tum culture conversion after 3 months (80). All patients re-
mained culture negative for up to 1 year. Sixteen percent of
patients relapsed after 12 to 24 months. If pyrazinamide was
included in the regimen, treatment response might have im-
proved, as pyrazinamide accelerates sputum culture conversion
rates significantly (14). Another study in TB patients did not
show a difference in efficacy between 600 mg or 750 mg ri-
fampin daily combined with 300 mg isoniazid for 20 weeks
(84). Recently, the EBA of 1,200 mg rifampin daily was studied
in 14 patients with pulmonary TB. The mean 2-day EBA was
almost twice as high as that of 600 mg rifampin (30).
(iv) Safety and tolerability. Little is known about the toler-
ability of higher than standard doses of rifampin. Past attempts
to use large intermittent rather than daily doses of rifampin
were met with a high incidence of the flu-like syndrome. This
was ascribed to the intermittency of dosing rather than the size
of the dose (16). Daily rifampin at 13 mg/kg was tolerated well
by Indonesian patients (133). Grade 1 and 2 hepatotoxicity was
more common in the higher-dose group (46% versus 20%; P
0.054), but none of the patients developed serious hepatotox-
icity. Five days of rifampin monotherapy at 1,200 mg was
tolerated well by patients in the EBA study (30). Higher doses
of rifampin did not cause tolerability problems in patients with
brucellosis (900 mg, 45 days) or cutaneous leishmaniasis (1,200
mg, divided in two doses, 28 days) (79, 143). The tolerability of
rifampin in other diseases was reviewed in 650 patients; it was
good with doses up to 1,200 mg but less favorable with doses of
1,800 mg (78).
(v) Discussion. Available data suggest that higher daily
doses of rifampin can shorten TB treatment. The maximum
tolerable dose of rifampin should be assessed when adminis-
tered alone and in combination with currently available drugs.
The EBA of a range of higher doses of rifampin given alone
and in combination should be investigated more extensively,
and phase II and III clinical trials with higher than standard
doses of rifampin in different multidrug regimens should be
performed. Rifampin is cheap and widely available, and phy-
sicians have experience with this drug. If increasing the dose of
rifampin proves to be safe and effective, this intervention could
be implemented broadly and quickly. Drawbacks of rifampin
are its inductive effect on the CYP450 enzyme system, which is
involved in the metabolism of many other drugs, and the in-
creasing rate of mycobacterial resistance to rifampin.
Rifapentine. Rifapentine (10 mg/kg) was approved for the
treatment of pulmonary TB by the U.S. Food and Drug Ad-
ministration (FDA) in 1998 (rifapentine [Priftin] package in-
sert, Hoechst Marion Roussel, Kansas City, MO). It allows for
intermittent dosing at wider intervals, which facilitates ob-
served treatment (102). However, regimens with rifapentine
and isoniazid once weekly in the continuation phase of treat-
ment are slightly inferior to regimens with rifampin and isoni-
azid twice weekly, especially in patients with cavitary TB (152,
165; rifapentine [Priftin] package insert, Hoechst Marion
Roussel, Kansas City, MO). A high rate of mycobacterial
monoresistance to rifamycins was seen in HIV-infected pa-
tients treated with rifapentine and isoniazid (9). The use of
rifapentine once weekly has therefore been restricted to HIV-
negative pulmonary TB patients without cavitation and with a
negative sputum culture after the intensive phase of treatment
(63). Higher than standard doses of rifapentine have shown the
potency to shorten TB treatment in mice, especially when
combined with moxifloxacin (130).
(i) Mechanism of action. Rifapentine is a cyclopentyl rifa-
mycin that, like other rifamycins, inhibits mycobacterial RNA
synthesis by binding to the -subunit of DNA-dependent RNA
polymerase (63, 102). Mutations in the gene coding for the
-subunit (rpoB) of the mycobacterial RNA polymerase lead
to complete resistance to all rifamycins (100, 172).
(ii) Pharmacokinetics. The pharmacokinetic properties of
rifapentine in the standard dose in adults are summarized in
Table 2 and described elsewhere (16, 76, 77, 101, 102, 123, 127,
TABLE 2. Pharmacokinetics of rifampin, rifapentine, moxifloxacin, and gatifloxacin
Drug (dose) Bioavailability(%)
AUC
(mg  h/liter) Cmax (mg/liter) tmax (h)
a t1/2 (h)b
Plasma
protein
binding (%)
Reference
Rifampin (10 mg/kg) 68 21.5 8–20 1.5–2.0 2–5 85 1, 16
Rifapentine (600 mg) Unknown 319–394 10–18 4.8–9 13–20 97 16, 63, 75–77, 102; rifapentine
(Priftin) package insert
(Hoechst Marion Roussel)
Moxifloxacin (400 mg) 86 26.9–39.3 2.5–4.3 (5.9)d 1–2 (0.7)d 9.2–15.6 (6.5)d 50 88, 119, 146
Gatifloxacin (400 mg) 96 30–51.3c 3.4 (3.7)d 1.5 (2.4)d 6.5–7.8 (5.0)d 20 88, 119, 139, 178
a tmax, time to Cmax.
b t1/2, half life.
c In steady state.
d Multiple doses in patients with pulmonary TB.
VOL. 53, 2009 MINIREVIEW 851
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151; rifapentine [Priftin] package insert, Hoechst Marion
Roussel, Kansas City, MO). When the dose of rifapentine was
increased from 600 to 900 or 1,200 mg in 35 TB patients, the
AUC increased by 39% or 61%, respectively (170). Rifapen-
tine induces the CYP450 enzyme system to a lesser extent than
rifampin (16). Rifapentine autoinduction—the phenomenon
that induction of the CYP450 enzyme system also increases
metabolism of the drug itself—was recently shown in a phase I
study: rifapentine AUC decreased by 20% after 7 days of
thrice-weekly rifapentine at 900 mg in 13 healthy volunteers
(34). Rifapentine (900 mg thrice weekly) reduced the AUC of
moxifloxacin (400 mg daily) by 17% in the same study.
(iii) Pharmacodynamics and efficacy. The MIC of rifapen-
tine ranges from 0.02 to 0.125 mg/liter, i.e., two to four times
lower than that of rifampin (8, 18, 31, 32, 101). When adjusted
for protein binding, the AUC/MIC ratio for rifapentine in
standard dose is 76.6 (AUC/MIC ratio for rifampin, 70.8)
(108).
Rifapentine is being evaluated with moxifloxacin as a com-
panion drug. A higher dose of rifapentine (15 mg/kg) with
moxifloxacin (100 mg/kg twice per day) in a once-weekly con-
tinuation-phase regimen in mice showed better sterilizing ac-
tivity than once-weekly rifapentine (15 mg/kg) and isoniazid
(75 mg/kg) or twice-weekly rifampin (10 mg/kg) and isoniazid
(75 mg/kg) (131). A twice-weekly regimen in mice containing
rifapentine (15 or 20 mg/kg), pyrazinamide (300 mg/kg), and
moxifloxacin (100 mg/kg), preceded by 2 weeks of daily ri-
fampin (10 mg/kg), pyrazinamide (150 mg/kg), and moxifloxa-
cin (100 mg/kg), resulted in stable cure after 4 months of
treatment (130). Substitutions of rifampin (10 mg/kg) by rifa-
pentine (10 mg/kg) and of isoniazid (25 mg/kg) by moxifloxacin
(100 mg/kg twice per day) in a daily standard regimen in mice
lead to bacillus eradication rates twice as fast as the standard
regimen (132). A recent study in mice showed that the main
sterilizing component in regimens containing rifapentine,
moxifloxacin, and pyrazinamide is rifapentine, rather than
moxifloxacin (110). An experiment in mice revealed a dramatic
increase of bactericidal activity with increased rifapentine dose
up to 80 mg/kg in a regimen of rifapentine, moxifloxacin (100
or 400 mg/kg), and pyrazinamide (150 or 600 mg/kg), indicat-
ing the potential of higher doses of rifapentine to shorten TB
treatment (129).
The International Consortium for Trials of Chemotherapeu-
tic Agents in Tuberculosis (INTERTB) is currently conducting
the RIFAQUIN trial with moxifloxacin (400 mg) instead of
isoniazid (300 mg) in the standard regimen and with rifapen-
tine once weekly (20 mg/kg for 4 months) or twice weekly (15
mg/kg for 2 months) in the continuation phase.
Rifapentine is also a candidate drug for latent TB. A once-
weekly, 3-month regimen of rifapentine (15 mg/kg) plus either
moxifloxacin (100 mg/kg) or isoniazid (75 mg/kg) was as active
as 6 months of daily isoniazid (25 mg/kg) in monotherapy in a
mouse model for latent TB (112). A regimen of rifapentine
(900 mg) plus isoniazid (900 mg) once weekly for 12 weeks was
tolerated better than daily rifampin (450 to 600 mg) plus
pyrazinamide (750 to 1,500 mg) for 8 weeks by patients with
latent TB. The regimen protected well against active TB (138).
(iv) Safety and tolerability. A study in 150 HIV-negative TB
patients treated with either 600, 900, or 1,200 mg rifapentine
plus isoniazid at 15 mg/kg once weekly in the continuation
phase showed good tolerability of the 900-mg dose and an
insignificant trend towards more adverse events in the
1,200-mg arm (12). In another study (35 patients), no associ-
ation between the occurrence of adverse events and a higher
dose of rifapentine (up to 1,200 mg) was found (170). Two of
14 healthy volunteers developed adverse events (grade 2 hep-
atitis and a flu-like syndrome with rash) after treatment with
daily moxifloxacin (400 mg) and thrice-weekly rifapentine (900
mg) (34).
(v) Discussion. Increasing the dose of rifapentine could
shorten TB treatment, especially in combination with moxi-
floxacin, and may be useful against latent TB as well. Rifap-
entine will cause fewer problems of drug-drug interactions
than rifampin. The optimum higher dose of rifapentine has not
yet been defined. The start of renewed rifapentine registration
trials with higher doses has been announced by Sanofi-Aventis
(presentation by D. Leboulleux at TBTC meeting, 16 to 17
May 2008, Toronto, Canada).
Rifabutin. Rifabutin is mainly used for the prevention and
treatment of disseminated Mycobacterium avium complex dis-
ease in patients with advanced HIV infection (15). The MIC of
rifabutin against rifampin-susceptible MTB strains is 0.08
mg/liter, 8 times less than the MIC of rifampin against the
same strains (31, 54, 156). In TB patients, the activity of ri-
fabutin was not greater than that of rifampin (50, 94). Further-
more, the occurrence of dose-related (450 mg) adverse
events, such as polyarthralgia, uveitis, flu-like syndrome, and
hepatitis (125, 142), is likely to deter any investigation into the
efficacy of higher than standard doses of rifabutin in TB treat-
ment.
NEW DRUGS FOR TB TREATMENT
Fluoroquinolones. The fluoroquinolones are a promising
class of drugs for the treatment of TB (43). In particular, they
are distributed broadly throughout the body, including within
cells, which explains their efficacy against intracellular myco-
bacteria (10, 46, 117, 148). The fluoroquinolones are registered
as second-line anti-TB drugs (11, 103, 174). Moxifloxacin and
gatifloxacin are candidates for shortening TB treatment, since
they have the lowest MICs (3, 38, 41, 44, 108) and greatest
bactericidal activity, as expressed in the rate of fall in CFU
count (44, 56, 66, 140). The approved dose for moxifloxacin
and gatifloxacin is 400 mg/day (Avelox [moxifloxacin hydro-
chloride] tablets, final draft package insert; FDA). While the
potential of moxifloxacin and gatifloxacin to shorten TB treat-
ment is being investigated in clinical trials, a new generation of
quinolones, including the promising TBK 613, is being devel-
oped in preclinical research (M. Spigelman, presented at the
1st International Workshop on Clinical Pharmacology of Tu-
berculosis Drugs, Toronto, Canada, 2008).
(i) Moxifloxacin. (a) Mechanism of action. Moxifloxacin is a
broad-spectrum 8-methoxy fluoroquinolone with activity against
both gram-positive and gram-negative bacteria, including
anaerobes (146, 147). It inhibits bacterial DNA gyrase, an
enzyme that is essential for the maintenance of DNA super-
coils, which are necessary for chromosomal replication (25, 92,
141, 145). The development of mycobacterial resistance to
fluoroquinolones has been described in MDR strains (13, 58,
163) and in strains from HIV-infected TB patients with a low
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CD4 count (47, 48). Fluoroquinolone resistance is due to step-
wise mutations in the quinolone resistance-determining region
of the mycobacterial gyrA and gyrB genes (46). No cross-resis-
tance with the first-line anti-TB drugs has been shown (46, 47,
56), but cross-resistance within the group of fluoroquinolones
was proved (2, 46, 72). A study in newly diagnosed TB patients
showed higher rates of M. tuberculosis resistance to fluoro-
quinolones in patients with prior exposure to fluoroquinolones
than in patients who were fluoroquinolone naïve (45). Other
studies did not find such an association (13, 58).
(b) Pharmacokinetics. The pharmacokinetic properties of
moxifloxacin in humans are summarized in Table 2. Moxifloxa-
cin is metabolized by glucuronidation and sulfation (phase II
metabolism) rather than by CYP450-mediated (phase I) me-
tabolism (106). Up to 20% of moxifloxacin is excreted unal-
tered in urine and 25% in feces (146). The AUC from 0 to 24 h
(AUC0–24) of moxifloxacin decreased by 27 to 31% when co-
administered with rifampin (106, 171). This could be due to
induction of phase II metabolic enzymes (uridine diphos-
phatase, glucuronosyltransferase, and sulfotransferase) by ri-
fampin (106). The clinical relevance of this interaction is un-
known.
(c) Pharmacodynamics and efficacy. In vitro studies with
moxifloxacin show MICs of 0.25 to 0.50 mg/liter (41, 66, 128,
140). The bactericidal activity of fluoroquinolones is generally
considered to be concentration dependent (10, 178), although
a recent report showed time-dependent killing as well (140).
The ratio of AUC to MIC is thought to be the best predictor
of fluoroquinolone efficacy in gram-negative, fast-multiplying
bacteria (46, 140, 178). It was shown in vitro and in vivo that
the greatest bactericidal activity occurs at AUC/MIC ratios of
100 to 125 or more (178). While it is unclear whether this also
applies to the slowly multiplying M. tuberculosis, this observa-
tion would suggest that moxifloxacin is the fluoroquinolone
with greatest efficacy, followed by gatifloxacin (AUC/MIC ra-
tios of 96 and 68, respectively, derived from in vitro and in vivo
work) (46). Aside from the AUC/MIC ratio, the other impor-
tant indicator of efficacy of concentration-dependent killers is
the Cmax/MIC ratio, which should be more than 8 to 12 for
effective killing of gram-negative bacteria (36, 108, 124, 178).
Data adapted from a single-oral-dose study in healthy volun-
teers showed that the Cmax/MIC90 ratio of moxifloxacin (400
mg) is 8.6 (88, 108).
In vitro studies and studies in mice showed enhanced bac-
tericidal activity of moxifloxacin and isoniazid when coadmin-
istered (41, 66, 85, 99, 179). Ethambutol adversely affected the
activity of moxifloxacin in vitro: it reduced moxifloxacin effi-
cacy by 80% (85). Moxifloxacin (100 mg/kg) was able to reduce
the time to culture conversion in mice by 2 months when
replacing isoniazid in the standard 6-month regimen (113,
114). This reduction was not found when moxifloxacin was
either added to the standard regimen or when it replaced any
of the other drugs. It is hypothesized that the superior activity
of 2 months of rifampin plus moxifloxacin plus pyrazinamide
followed by 4 months of rifampin plus moxifloxacin (2RMZ/
4RM) to 2RHZ/4RH is caused by a synergistic activity of
rifampin, moxifloxacin, and pyrazinamide or antagonistic ac-
tivity of rifampin, isoniazid, and pyrazinamide (113).
Moxifloxacin efficacy has also been shown in humans. EBA
studies in newly diagnosed pulmonary TB patients showed
comparable activity of moxifloxacin (400 mg) and isoniazid
(300 mg or 6 mg/kg) (51, 122). The VT50 (the time needed to
kill 50% of viable bacteria) of isoniazid was lower than that of
both rifampin and moxifloxacin. The EBA and VT50 of com-
bined moxifloxacin and isoniazid did not differ significantly
from the two drugs in monotherapy. Based on these results, no
antagonistic effect of adding moxifloxacin to the standard, iso-
niazid-containing regimen is expected, nor will it enhance the
bactericidal activity of the regimen (42). The effect of replacing
ethambutol with moxifloxacin in the standard regimen on the
2-month sputum culture conversion rate was analyzed in 277
patients with pulmonary TB from African and North American
sites (17). No difference in percentage of negative cultures
after 2 months of treatment (71% and 71%) was found. How-
ever, more patients treated with moxifloxacin had negative
cultures after 4 weeks of treatment than patients treated with
ethambutol (37% versus 26%; P  0.05). A comparable study
is ongoing in Brazil (71). The Gatifloxacin for TB Study Team
(OFLOTUB) performed a phase II clinical trial in which
ethambutol in the standard regimen was replaced by gatifloxa-
cin, moxifloxacin, or ofloxacin (135). The regimen with moxi-
floxacin caused the fastest decrease in CFU during the early
phase of a biexponential fall (in a nonlinear model that differ-
entiates between quickly and slowly eliminated bacilli) (28,
135). Both moxifloxacin and gatifloxacin accelerated bacillary
elimination significantly in the late phase. The percentage of
negative sputum cultures after 2 months of treatment did not
differ significantly between the treatment groups (82% versus
77% on solid medium and 40% versus 44% on liquid medium
[in MGIT] for moxifloxacin versus gatifloxacin, respectively)
(135). Two-month sputum culture conversion rates have also
been evaluated in a double-blind randomized controlled trial
in which isoniazid in the standard regimen was replaced with
moxifloxacin (TBTC study 28). Culture conversion after 8
weeks of treatment was achieved in 60% of patients treated
with the moxifloxacin-containing regimen and in 55% of pa-
tients using isoniazid (J. Grosset, presented at the 1st Interna-
tional Workshop on Clinical Pharmacology of Tuberculosis
Drugs, Toronto, Canada, 2008). A multicenter three-armed
REMoxTB trial in which the standard regimen is compared
to (i) a regimen of 2RHZM/2RHM and (ii) a regimen of
2RMZE/2RM has recently started. The possibility of combin-
ing moxifloxacin with rifapentine, two agents with a long half-
life, is explored in the RIFAQUIN trial (see section about
rifapentine) (85, 130, 131, 167). Finally, moxifloxacin could be
of use in the treatment of latent TB. The combination of 3
months of once-weekly moxifloxacin and rifapentine was as
effective as 6 months of isoniazid monotherapy in a mouse
model for latent TB (112).
(d) Safety and tolerability. A single dose moxifloxacin of up to
800 mg was tolerated well (88, 146, 147). Little is known about
the long-term tolerability in TB patients. Moxifloxacin (400
mg, administered for an average of 6.3 months) was withdrawn
in 4 of 38 TB patients because of a major adverse event (in-
cluding nausea, vomiting, muscle pain, tremors, insomnia, and
dizziness), but no irreversible or fatal events occurred (23). In
another study, no toxicity was experienced by patients who
were treated with moxifloxacin, rifampin, and isoniazid for 6
months (164). Prolongation of QT time has been seen in pa-
tients using moxifloxacin for a variety of other bacterial infec-
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tions (Avelox [moxifloxacin hydrochloride] tablets, final draft
package insert; FDA). In February 2008, Bayer distributed a
“Dear Doctor” letter warning physicians about rare but se-
vere hepatological and dermatological adverse events asso-
ciated with moxifloxacin. In July 2008 the European Medi-
cines Agency (EMEA) sent out a review on the association of
moxifloxacin and hepatological problems. It was concluded
that the benefits of moxifloxacin in treatment of respiratory
tract infections outweigh the risks, but its use should be re-
stricted (37).
(e) Discussion. Moxifloxacin is a promising drug that could
shorten TB treatment. However, the optimal dose of moxi-
floxacin in TB treatment must be evaluated with respect to the
recently observed decrease in AUC0-24 when coadministered
with rifampin. Furthermore, concerns have been raised about
the development of mycobacterial resistance against fluoro-
quinolones and the association between resistance and the
widespread use of fluoroquinolones for other infections (35).
The efficacy studies in mice and humans revealed ambiguous
results. While culture conversion rates increased in mice when
isoniazid was replaced by moxifloxacin in the standard regi-
men, this was not shown in humans, nor did moxifloxacin show
better early bactericidal activity than isoniazid in humans. Re-
placing ethambutol by moxifloxacin in the standard regimen in
humans also did not improve culture conversion rates convinc-
ingly. The optimal moxifloxacin-including regimen has yet to
be found. Finally, the adverse events of moxifloxacin require
extended evaluation.
(ii) Gatifloxacin. (a) Mechanism of action. Like the other
fluoroquinolones, gatifloxacin blocks the bacterial DNA
gyrase, thereby preventing chromosomal replication (25, 92, 141,
145). Gatifloxacin and moxifloxacin show cross-resistance (2,
46, 72). The mechanism of resistance is described in the section
on moxifloxacin.
(b) Pharmacokinetics. Table 2 shows the pharmacokinetic
properties of gatifloxacin. The elimination route of gatifloxacin
is predominantly renal; 77% of the oral dose is excreted in
urine (88). The elimination time of gatifloxacin was prolonged
in 22 healthy volunteers who received a single dose of a fixed-
dose combination of rifampin, isoniazid, pyrazinamide, and
gatifloxacin (600, 300, 1,600, and 400 mg, respectively). It led to
a 14% increase in AUC of gatifloxacin (and a 19% reduction of
rifampin AUC) (93).
(c) Pharmacodynamics and efficacy. The MICs of gatifloxacin
range from 0.2 to 0.5 mg/liter (38, 108, 128, 153, 154), resulting
in AUC/MIC90 ratios of 60 to 68 and Cmax/MIC90 ratios of 6.8
to 8.4 (adapted from results of studies in mice and healthy
volunteers) (46, 108).
In vitro studies and studies in mice showed improved activity
of rifampin and isoniazid when gatifloxacin was added and
even more when the regimen also included pyrazinamide (26,
81, 87). Ethambutol interfered with gatifloxacin in vitro as it
did with moxifloxacin: it caused a remarkable increase in the
MIC90 of gatifloxacin (87). When gatifloxacin (100 mg/kg) was
combined with ethionamide (75 mg/kg) and ethambutol (100
mg/kg) in mice, greater bactericidal activity was achieved than
with a 20 mg/kg rifampin plus 25 mg/kg isoniazid regimen (3).
The addition of pyrazinamide (150 mg/kg) to gatifloxacin/ethi-
onamide/ethambutol did not improve activity but yielded sta-
ble cures after 12 weeks of treatment and 8 weeks of observa-
tion, whereas the regimen without pyrazinamide did not (27).
A multicenter trial of the OFLOTUB consortium is enroll-
ing patients at five African sites. It compares the efficacy and
tolerability of a 4-month regimen of 2 months of rifampin plus
isoniazid plus pyrazinamide plus gatifloxacin followed by 2
months of rifampin plus isoniazid plus gatifloxacin (2RHZG/
2RHG) to the standard 2RHZE/4RH regimen (71). The
OFLOTUB consortium also evaluated the fall in CFU count in
patients enrolled in the same trial (see section on moxifloxa-
cin) (135).
(d) Safety and tolerability. A single dose of gatifloxacin (400
mg) was tolerated well (88). Only mild adverse events were
reported in patients with respiratory tract infections who were
treated with gatifloxacin at 100 to 400 mg/day for 5 to 12 days
(169). An increased risk of dysglycemia was described in el-
derly patients using gatifloxacin for a variety of bacterial infec-
tions (118). Elderly patients with hypoglycemia or hyperglyce-
mia were 4 or 17 times more likely to have used gatifloxacin
than controls. The results of this study forced the OFLOTUB
study group to tighten their exclusion criteria and to strengthen
their monitoring of dysglycemic events (71). No dysglycemic
events related to gatifloxacin use were reported in an earlier
study that focused on the fall in CFU (135).
(e) Discussion. Gatifloxacin has many of the favorable fea-
tures of moxifloxacin. However, the risk of mycobacterial re-
sistance development and the recently found association be-
tween gatifloxacin and dysglycemic events are concerns. In
vitro studies and studies in mice revealed contradictory results.
While ethambutol reduced gatifloxacin activity in vitro, the
combination of ethambutol, ethionamide, and gatifloxacin was
highly effective in mice.
Diarylquinolines. Diarylquinolines have been identified in a
process of screening various compounds for potential anti-TB
activity (4). The most active diarylquinoline (TMC207, also
called R 207910, or compound J) is currently being evaluated
in phase II clinical trials at a dose of 400 mg/day (71).
(i) TMC207. (a) Mechanism of action. TMC207 inhibits the
mycobacterial ATP synthase enzyme (4, 29). TMC207 has
shown equal activity in susceptible and MDR strains. No cross-
resistance with available drugs is expected since the target of
the diarylquinolines differs from that of the currently avail-
able anti-TB drugs (4, 161). Mycobacteria that are resistant
to TMC207 in vitro show mutations in the atpE gene, which
encodes subunit c of ATP synthase (121).
(b) Pharmacokinetics. Oral administration with a meal re-
sults in a twofold increase of serum TMC207 concentrations
(71). The Cmax is reached after 5 h; the half-life is long: about
24 h in humans. The pharmacokinetics of TMC207 show lin-
earity with dose (4). TMC207 is metabolized by the CYP450
3A4 enzyme to an active N-monodesmethyl metabolite (M2)
(134). Rifampin reduces plasma TMC207 concentrations by
50%; however, a recent study in mice showed significant
activity of TMC207 even with a 50% reduction in exposure,
indicating that the relevance of this interaction is question-
able (71, 86). No drug-drug interactions were observed be-
tween TMC207 and isoniazid plus pyrazinamide (K. De
Beule and R. van Heeswijk, presented at the 1st Interna-
tional Workshop on Clinical Pharmacology of Tuberculosis
Drugs, Toronto, Canada). Steady-state concentrations in
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humans take more than 7 days to establish due to the ex-
tensive tissue distribution of TMC207 (71).
(c) Pharmacodynamics and efficacy. In vitro studies show
MICs ranging from 0.030 to 0.120 g/ml in both fully suscep-
tible and MDR strains (4, 59). The in vitro activity of TMC207
did not increase with increasing drug concentration, suggesting
time-dependent rather than concentration-dependent killing.
The activity of TMC207 is limited to mycobacterial species
only (4).
Treatment with TMC207 (25 mg/kg), isoniazid (25 mg/kg),
and pyrazinamide (150 mg/kg), and with TMC207, rifampin
(10 mg/kg), and pyrazinamide yielded 100% negative lung cul-
tures in mice after only 2 months of treatment. When any of
the drugs in the standard regimen was replaced with TMC207
(25 mg/kg), the bactericidal activity improved (4). Regimens
based on the standard anti-TB drugs and/or moxifloxacin that
contained both pyrazinamide and TMC207 were more active
than regimens without these two drugs. A 2-month regimen of
once-weekly TMC207 (125 mg/kg), pyrazinamide (300 mg/kg),
and rifapentine (15 mg/kg) was more active than rifampin (10
mg/kg), isoniazid (25 mg/kg), and pyrazinamide (150 mg/kg)
five times per week (166). These results suggest synergistic
activity of TMC207 and pyrazinamide in mice (60).
The guinea pig model was used to demonstrate sterilizing
activity of TMC207. Almost complete eradication of primary
and secondary lung lesions was achieved after 6 weeks of
TMC207 monotherapy (15 mg/kg), whereas the standard reg-
imen had limited effect (83).
An EBA study was done in which patients with pulmonary
TB received various doses of TMC207, rifampin, or isoniazid
in monotherapy for 7 days. The EBA of both rifampin and
isoniazid was better than that of TMC207. Only a dose of 400
mg TMC207 showed an EBA between days 4 and 7 of the same
magnitude as that of rifampin and isoniazid in the same period
(134). Because of the pharmacokinetic interaction between
rifampin and TMC207, the primary focus in the development
of TMC207 is now on regimens without rifampin. Recently, a
multicenter phase II study in 200 patients with MDR TB was
started in which a standard second-line, rifampin-free regimen
is compared with the same regimen plus TMC207 (71).
(d) Safety and tolerability. No serious adverse events were
reported in single-dose (up to 700 mg) and multiple-dose (up
to 400 mg) studies in healthy, male volunteers (see suppporting
data in reference 4). In the EBA study, no adverse events
related to the study drugs were encountered (71, 134).
(e) Discussion. TMC207 is a new, promising compound that
has greater bactericidal activity than the standard first-line
regimen in mice. It is active in susceptible and MDR strains.
However, the EBA of TMC207 in humans is not as good as
that of rifampin and isoniazid. The variability of serum
TMC207 concentrations with food intake is a disadvantage.
TMC207 could be of use in rifampin-free regimens against
MDR and XDR TB. Interactions between TMC207 and rifa-
pentine, another agent with a long half-life, should be investi-
gated.
Nitroimidazopyrans. The nitroimidazopyrans have been de-
rived from the bicyclic nitroimidazofurans that were originally
developed for cancer chemotherapy but also exhibited activity
against actively growing and dormant M. tuberculosis (116,
149). The compounds are structurally related to metronidazole
(7, 149). PA-824 (a nitroimidazo-oxazine) and OPC-67683 (a
dihydroimidazo-oxazole) are currently being investigated in
clinical trials (144).
(i) PA-824. (a) Mechanism of action. PA-824 is a prodrug
that needs the mycobacterial glucose-6-phosphate dehydroge-
nase (FDG1) or its cofactor, coenzyme F420, to be transformed
into an active form (89, 149). Activated PA-824 inhibits the
synthesis of proteins and cell wall lipids. PA-824 activity is
limited to M. tuberculosis complex (90, 149). PA-824 is active in
susceptible and resistant M. tuberculosis strains. No cross-re-
sistance with standard anti-TB drugs has been observed (149).
Mutations in the mycobacterial genes fbiA, fbiB, and fbiC lead
to impaired coenzyme F420 synthesis and therefore resistance
to PA-824 (21, 22). Mutations in the Rv3547 gene, encoding a
protein with unknown function, have been described in PA-824
resistant strains. Complementing these mutants with intact
Rv3547 fully restored the ability of the mutants to metabolize
PA-824. This suggests mediation of a highly specific protein,
next to FGD1 and coenzyme F420, in PA-824 activity (89).
(b) Pharmacokinetics. Serum PA-824 concentrations in mice
are not influenced by coadministration of rifampin, isoniazid,
and pyrazinamide in various combinations, and PA-824 does
not influence concentrations of the latter drugs in serum (109).
PA-824 is currently being investigated in phase I clinical trials
under the auspices of the GATB. Studies in healthy volunteers
showed a half-life of about 18 h and a time to reach Cmax of 4
to 5 h. About 65% of PA-824 is excreted in urine and 26% in
feces (71).
(c) Pharmacodynamics and efficacy. In vitro studies showed
MICs of PA-824 against fully susceptible and MDR strains
ranging from 0.015 to 0.25 g/ml. PA-824 activity is concen-
tration dependent (82, 149, 162).
The bactericidal activity of PA-824 (25 to 50 mg/kg) was
comparable to that of isoniazid (25 mg/kg) in mice and guinea
pigs (82, 149, 159, 162) and to those of rifampin (20 mg/kg) and
moxifloxacin (100 mg/kg) in mice (82). PA-824 showed greater
activity than isoniazid and moxifloxacin in vitro and in mice
and comparable activity to combination therapy with rifampin
and isoniazid (57, 82, 162). PA-824 (100 mg/kg) has been
incorporated in the standard regimen in mice to evaluate its
potential to shorten treatment duration. Only the regimen in
which isoniazid was replaced with PA-824 achieved faster lung
culture conversion and a lower CFU count after 2 months of
treatment than the standard regimen. However, relapse rates
were the same in these regimens (109). The sterilizing activity
of a regimen containing PA-824 (100 mg/kg), moxifloxacin
(100 mg/kg), and pyrazinamide (150 mg/kg) was recently found
to be better than that of rifampin (10 mg/kg), isoniazid (25
mg/kg), and pyrazinamide (150 mg/kg) in mice, indicating that
PA-824 could be incorporated in a rifampin-free regimen to
treat MDR TB (111).
PA-824 (100 mg/kg) was highly active in a mouse model for
latent TB when combined with moxifloxacin (100 mg/kg) (112).
An extended EBA study in humans with daily PA-824 doses of
200 to 1,200 mg over 14 days is ongoing in South Africa.
Results are expected soon (M. Spigelman, presented at the 1st
International Workshop on Clinical Pharmacology of Tuber-
culosis Drugs, Toronto, Canada, 2008).
(d) Safety and tolerability. Single PA-824 doses ranging from
50 to 1,500 mg were tolerated well by healthy volunteers, but
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multiple doses of 1,000 mg were associated with a moderate,
reversible increase in creatinine. This renal effect of PA-824
was found to be of insignificant clinical relevance in consecu-
tive studies (M. Spigelman, presented at the 1st International
Workshop on Clinical Pharmacology of Tuberculosis Drugs,
Toronto, Canada, 2008).
(e) Discussion. In mice, PA-824 seems most promising in
regimens without isoniazid. However, no regimen in which
PA-824 was combined with the standard, first-line anti-TB
drugs in mice has convincingly shown the potential of short-
ening treatment duration. No additive or synergistic activity of
PA-824 with the first-line drugs has been shown. PA-824 could
be developed for the treatment of latent TB together with
moxifloxacin, since the combination was highly active in a
mouse model for latent TB. Its activity against drug-susceptible
and drug-resistant M. tuberculosis strains must be evaluated in
regimens with second-line (or new) anti-TB drugs.
(ii) OPC-67683. (a) Mechanism of action. OPC-67683 is a
mycolic acid biosynthesis inhibitor (137). While isoniazid in-
hibits the synthesis of all mycolic acid subclasses, OPC-67683
inhibits methoxy and ketomycolic acid synthesis only (91).
OPC-67683 has to be activated by M. tuberculosis to exert its
activity. Mutations in the mycobacterial Rv3547 gene found in
OPC-67683 resistant M. tuberculosis strains suggest that this
gene codes for the key enzyme in activating OPC-67683 (as
well as PA-824) (91, 158).
(b) Pharmacokinetics. Studies in healthy volunteers showed a
more than dose-proportional increase in systemic exposure to
OPC-67683 with a stepwise increase of the dose from 5 to 400
mg (71). Absorption rates were higher when OPC-67683 was
administered with a high-fat meal. OPC-67683 was consecu-
tively analyzed in a different administration formula. This im-
proved systemic absorption (71). The newer formula is used in
ongoing evaluations of OPC-67683. OPC-67683 does not affect
the activity of liver microsome enzymes, nor is it affected by
activated liver enzymes (91). Interactions with drugs that are
metabolized by these enzymes are therefore not expected.
(c) Pharmacodynamics and efficacy. The MICs of OPC-67683
are equal in drug-susceptible and -resistant M. tuberculosis
strains and range from 0.006 to 0.024 g/ml (91, 137). OPC-
67683 exhibits concentration-dependent activity also against
intracellular M. tuberculosis (91, 136).
The in vitro intracellular activity of OPC-67683 was better
than that of isoniazid and PA-824 and as good as that of
rifampin (91). OPC-67683 showed sterilizing activity that was
superior to that of isoniazid and equal to that of rifampin in an
in vitro model of drug-tolerant M. tuberculosis, representing
semidormant bacilli (136). No antagonism of OPC-67683 with
rifampin, isoniazid, ethambutol, and streptomycin was shown
in vitro (91).
In mice, a regimen of OPC-67683 (2.5 mg/kg), rifampin (5
mg/kg), and pyrazinamide (100 mg/kg) achieved faster eradi-
cation of bacilli than the standard RHZE regimen (5, 10, 100,
and 100 mg/kg, respectively). Whereas no mycobacterial colo-
nies were detected after 4 months of treatment with the OPC-
67683-containing regimen, colonies were still detected after 6
months of treatment with the standard regimen (91).
The EBA of 400 mg OPC-67683 in patients with pulmonary
TB was low during the first 4 days. From day 4 onwards, a
significant decrease in CFU was seen. This activity is currently
being explored in an extended (14 days) EBA study (71).
(d) Safety and tolerability. OPC-67683 in multiple doses up to
400 mg was tolerated well by healthy volunteers. No serious
adverse events were reported (71).
(e) Discussion. OPC-67683 is a promising new anti-TB drug
with bactericidal and sterilizing activity in vitro and in mice. It
could be useful in treatment of MDR and XDR TB. Its opti-
mal formulation and its role in TB treatment in humans still
need to be established. The low EBA is not favorable.
Diamines. A library of more than 60,000 compounds was
generated by synthesizing ethambutol analogues with 1,2-dia-
mine pharmacophore (20, 67, 70). So far, the most promising
diamine candidate from this library for TB treatment is SQ109
(70).
(i) SQ109. (a) Mechanism of action. SQ109 inhibits myco-
bacterial cell wall synthesis; the exact target is not yet known
(20). Since resistance rates to SQ109 are low, it is thought that
two mycobacterial gene changes are needed to result in resis-
tance. Therefore, SQ109 may have more than one target in M.
tuberculosis (71).
(b) Pharmacokinetics. SQ109 undergoes a first-pass step in
the liver before it enters the systemic circulation. Liver
microsomes convert SQ109 in four predominant metabo-
lites. CYP2D6 and CYP2C19 enzymes are involved in
SQ109 metabolism; CYP3A4 has little effect on SQ109 (68).
It has been suggested that SQ109 is a prodrug that needs
activation by mycobacterial CYP enzymes (20). Results
from a recent drug-drug interaction study in rats suggest
that SQ109 induces its own metabolism (55). SQ109 binding
to plasma proteins ranges from 6 to 23% in humans, mice,
rats, and dogs (68). Binding to tissue proteins is higher than
that to plasma proteins (20). SQ109 has a long half-life (61
h) in humans (160).
(c) Pharmacodynamics and efficacy. The MIC of SQ109
ranged from 0.16 to 0.64 mg/liter in susceptible and drug-
resistant MTB isolates, including ethambutol-resistant strains
(20, 71). SQ109 also exhibits bactericidal activity within mac-
rophages (67, 69, 70). Its activity is concentration dependent
(69).
Synergistic activity was shown in vitro between SQ109 and
isoniazid and especially rifampin. Synergy was even present in
rifampin-resistant strains. Streptomycin had an additive effect
on SQ109 activity; ethambutol and pyrazinamide had no effect
on the activity of SQ109 (20). Four weeks of monotherapy with
SQ109 (0.1 to 25 mg/kg) in mice resulted in a reduction of
mycobacterial load in spleen and lungs that was comparable to
the effect of treatment with ethambutol (100 mg/kg) but less
than that of treatment with isoniazid (25 mg/kg) (69). When
ethambutol (100 mg/kg) was substituted for by SQ109 (10
mg/kg) in an 8-week regimen of rifampin (20 mg/kg) and iso-
niazid (25 mg/kg), with or without pyrazinamide (150 mg/kg),
in mice with chronic TB, the mycobacterial load was 1.5 log10
lower than with the standard RHZE regimen (107).
(d) Safety and tolerability. No adverse events were reported
in a phase I single-dose study (71). Multiple doses of SQ109
(up to 300 mg) were tolerated well by healthy volunteers (160).
(e) Discussion. SQ109 is a potential anti-TB drug that has
entered phase I/II clinical trials. It has low MICs against both
susceptible and resistant MTB strains. SQ109 has different and
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more favorable properties than ethambutol, suggesting that it
should be regarded as a truly new diamine, and not just as an
ethambutol analogue. SQ109 could be included in regimens
containing rifampin and isoniazid, since synergism with both
drugs has been shown. Clinical trials are ongoing to establish
its future role in TB treatment.
Pyrroles. In the search for compounds with activity against
mycobacteria and fungi, several pyrrole derivatives have been
developed. LL3858 is being investigated in phase I clinical
trials (5, 71). A fixed-dose combination called LL3848, con-
taining LL3858 and the standard, first-line anti-TB drugs, is
also being developed (126).
(i) LL3858. (a) Mechanism of action. The mycobacterial tar-
get of LL3858 is not yet known. Since LL3858 is active against
M. tuberculosis strains that are resistant to available anti-TB
drugs, the target probably differs from the targets of the cur-
rently used drugs.
(b) Pharmacokinetics. No data about the pharmacokinetics
of LL3858 in humans are available yet (157).
(c) Pharmacodynamics and efficacy. The MIC90 of LL3858
for MTB is 0.25 g/ml. LL3858 exhibits concentration-depen-
dent activity (5). LL3858 (12.5 mg/kg) reduced the mycobac-
terial load in mice to a greater extent than isoniazid. Regimens
of 8 weeks of LL3858, isoniazid, and rifampin with or without
pyrazinamide sterilized lungs and spleens of 3 of 6 and 4 of 6
mice, respectively. When the treatment period was extended to
12 weeks, complete sterilization of the target organs was
achieved in 6 of 6 mice (5, 157).
(d) Tolerability. The tolerability of LL3858 is currently being
investigated in phase I clinical trials (157).
(e) Discussion. The pyrroles are a new class of compounds
with promising activity against M. tuberculosis, atypical myco-
bacteria, and fungi. The pyrrole derivative LL3858 has reached
phase I clinical trials.
DISCUSSION: THE WAY FORWARD
Several new drugs for TB treatment are being evaluated in
clinical trials. Available data reveal different properties of the
agents (Table 3) and provoke speculation about future direc-
tions. Higher doses of the rifamycins are promising and may be
the first to be implemented in a regimen of shorter duration.
Moxifloxacin and gatifloxacin might shorten TB treatment,
possibly in combination with rifapentine. Coadministration of
moxifloxacin and PA-824 could be active against latent TB.
PA-824 and TMC 207 are candidates for a rifampin-free reg-
imen for treatment of MDR and XDR TB. SQ109, on the
other hand, could enhance the activity of rifampin-containing
regimens.
Unfortunately, shorter treatment regimens based on the
new agents discussed here are likely to take at least another
decade to be fully developed and implemented in clinical
practice. Since not all new agents will succeed in clinically
useful regimens, and since only a few drugs are currently in
preclinical development, more new agents are needed.
Therefore, urgent attention should be paid to the develop-
ment of new drugs; this requires more involvement of large
pharmaceutical industries. The development of new drugs
should get a programmatic approach in which a series of
consecutive studies are properly planned, while keeping the
desired end product in mind (J. Gheuens, presented at the
TBTC meeting, Toronto, Canada, 2008). Moreover, the de-
velopment of various agents must be coordinated, since a
single new drug might not be very promising in a regimen
with the standard anti-TB drugs, but could be highly active
in combination with other new drugs. The potential of bi-
functional molecules with more than one target in MTB is
currently being explored (M. Spigelman, presented at the
1st International Workshop on Clinical Pharmacology of
Tuberculosis Drugs, Toronto, Canada, 2008). Initiatives
such as the GATB have an important role in facilitating
cooperation in drug development.
Ways to shorten clinical trials with new TB drugs should be
explored. The evaluation of surrogate biomarkers that predict
the likelihood of relapse, such as serial sputum colony counts
and molecular markers, should be incorporated into clinical
trials as much as possible. Validated surrogate markers will
reduce the time it takes to assess the efficacy of new agents.
TABLE 3. Overview of anti-TB drugs in the clinical pipeline
Drug Trialphase
Potential
to
shorten
treatment
Acceptable toxicity profile
Active
against
MDR TB
Useful in HIV-infected
patients with TB
Active against latent
TBa Interaction with rifampin
High-dose
rifampin
II Yes To be established Limited Yes, but not coadministered
with protease inhibitors
Yes, but not first
choice
NAb
High-dose
rifapentine
II Yesc To be established Limited To be established Yes NA
Moxifloxacin III Yes Yes Yes Yes Yesc Yes; reduced AUC of
moxifloxacin by 30%
Gatifloxacin III Yes Yes (caution: dysglycemia in
elderly)
Yes Yes Unkown Possible
TMC207 II Yesc To be established Yes Unknown Unknown Yes; reduced serum TMC207
concn by 50%
PA-824 II Doubtful Yes (moderate increase in
creatinine observed)
Yes Unknown Yesc No
OPC-67683 I/II Yesc To be established Yes Unknown Unknown No
SQ109 I/II Yesc To be established Yes Unknown Unknown Synergism in vitro
LL3858 I Yesc Unknown Yes Unknown Unknown Synergism in vitro
a Latent TB is the situation in which a host is infected with Mycobacterium tuberculosis but has not developed symptoms.
b NA, not applicable.
c Results from preclinical data.
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Special groups of patients should be addressed in clinical
trials. Since TB is a major problem in patients with HIV, these
patients should be included in clinical research on new anti-TB
drugs as early as possible. Likewise, the development of im-
proved TB treatment regimens for children should get high
priority (33). Effective treatment regimens against MDR and
XDR TB should be developed urgently.
To facilitate clinical trials, research capacity should be
strengthened in developing countries, where the TB burden
is highest.
Finally, control of the TB epidemic implies more than
developing new drugs. The diagnostic and therapeutic facil-
ities of health care centers in developing countries should be
improved, and the socioeconomic status and general welfare
of patients (including nutritional and HIV status) should be
addressed to help eradicate TB.
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ADDENDUM IN PROOF
The potential of PA-824 to shorten TB treatment duration when
combined with the standard, first-line anti-TB drugs was recently
reassessed in the mouse model (R. Tasneen, S. Tyagi, K. Williams,
J. Grosset, and E. Nuermberger, Antimicrob. Agents Chemother.
52:3664–3668, 2008). Mice treated with rifampin (10 mg/kg), PA-
824 (100 mg/kg), and pyrazinamide (150 mg/kg) remained free of
relapse after 4 months of treatment, while 15% of mice treated with
a 4-month regimen of rifampin, isoniazid (25 mg/kg), and pyrazin-
amide relapsed. The combinations of PA-824 and pyrazinamide and
of PA-824 and rifampin displayed synergistic activity in the same
study. Results from this study hold promise for PA-824 to shorten
TB treatment duration in combination with first-line drugs.
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